Compare Agilent Technologies Inc (A) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Huntington Ingalls Industries Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Huntington Ingalls Industries Inc trades at $328 (market cap $13.04B). The key difference: Agilent Technologies Inc is far larger — about 3.2× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| A | HII | |
|---|---|---|
Market Cap | $42.00B | $13.04B |
Sector | Health | Technology |
52-Week High | $157.20 | $453.73 |
52-Week Low | $110.24 | $265.40 |
Enterprise Value | $43.55B | $15.96B |
Dividend Yield | 0.69% | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
HII trades at $324.48, up 0.85% on the day, with a bullish technical signal driven by moving averages and recent contract wins. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Key developments include a $900 million robotics partnership and new submarine contracts, supporting a positive outlook.
The stock offers upside to the consensus price target of $359.67, with 44% of analysts rating it Buy. Risks include execution challenges in shipbuilding and political headwinds. Fundamentals are solid with a P/E of 19.7 and ROE of 12.97%, but overbought RSI levels near 85.92 suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
